US Obesity Payer & HTA

Medicare Part D has excluded anti-obesity medications by statute since the program began; drugs used for weight loss are a non-covered category. That exclusion still stands. But in March 2024 CMS clarified that an anti-obesity medication approved for an additional medically-accepted indication can be a covered Part D drug for that use. When the FDA approved Wegovy (semaglutide 2.4mg) to reduce cardiovascular events in adults with obesity or overweight and established cardiovascular disease, on the strength of the SELECT trial's 20% MACE reduction, it opened Part D coverage for that CVD segment. Weight loss alone remains excluded; Ozempic, Rybelsus and Mounjaro are covered only for type 2 diabetes. The result is a coverage architecture built on comorbidity, not obesity itself.

Pricing and HTA cut in different directions. On list price, Wegovy carries a WAC near $1,349 per month and Zepbound (tirzepatide) near $1,060. Under the Inflation Reduction Act's second negotiation cycle, CMS selected semaglutide for initial-price-applicability-year 2027; because negotiation applies at the active-ingredient level, the Maximum Fair Price ($274 for a 30-day supply, a 71% cut off Ozempic's ~$959 list) covers all Novo Nordisk semaglutide products, Ozempic, Rybelsus and Wegovy, effective January 1, 2027. Tirzepatide is newer and appears on no CMS selected-drug list. On value, ICER's December 16, 2025 final evidence report reached the opposite conclusion to most single-source obesity assessments: its independent panel rated injectable and oral semaglutide and tirzepatide 'high' long-term value at current pricing, with health-benefit price benchmarks of $9,100–$12,500 a year for injectable semaglutide and $11,700–$16,100 for tirzepatide.

Every AXLRx payer brief is built from primary regulatory and HTA sources: CMS negotiation documentation and coverage guidance, ICER evidence reports, manufacturer pricing, and live payer formulary and prior-authorisation policy documents, not secondary summaries. Every factual claim is independently verified before inclusion.

US Obesity Payer & HTA sources: CMS Medicare Drug Price Negotiation Program selected-drug list and negotiated prices for IPAY 2027 (semaglutide), effective January 1, 2027; CMS March 2024 Part D coverage guidance on anti-obesity medications with an additional medically-accepted indication; ICER Final Evidence Report on obesity management (December 16, 2025); NEJM SELECT cardiovascular outcomes trial (PMID 37952131); and major commercial payer PA policy documents (UHC, CVS/Aetna, Cigna).